President Trump Signs Executive Order to Reclassify Marijuana, Finally Acknowledging Medical Justice

On December 18, 2025, President Donald Trump, under mounting public pressure and in the face of overwhelming scientific consensus, signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III controlled substance under federal law. This long-awaited change finally acknowledges the medical use of marijuana, a fact activists and healthcare advocates have championed for years, and aims to ease the draconian restrictions that have stifled research and the growth of the cannabis industry, particularly harming communities of color.

"I’m pleased to announce that I will be signing an Executive Order to reschedule marijuana from a Schedule I to a Schedule III controlled substance with legitimate medical uses," President Trump stated during the signing, a statement that, while welcome, comes after years of inaction and resistance from conservative lawmakers.

The reclassification aligns marijuana with substances like ketamine and certain prescription medications, a long-overdue recognition of its accepted medical use and lower potential for abuse. While this move does not go far enough to legalize marijuana for recreational use at the federal level, it is expected to facilitate long-stifled medical research and reduce the oppressive regulatory burdens that have hampered the cannabis industry and denied patients access to alternative treatments.

The executive order also initiates a Medicare pilot program to reimburse patients for products containing cannabidiol (CBD), a non-psychoactive compound derived from cannabis. This program is a crucial step toward providing alternative treatments for patients, especially those managing chronic pain, and begins to address the failures of the profit-driven pharmaceutical industry.

The reclassification process requires formal rule-making by the Drug Enforcement Administration (DEA) and is subject to public input. The Department of Health and Human Services (HHS) has been directed to develop research methods utilizing real-world evidence to study the long-term health effects of medical marijuana and hemp-derived cannabinoid products, finally prioritizing public health over outdated prohibitionist ideology.

Public opinion on marijuana legalization has evolved, with 64% of Americans supporting legalization, according to recent surveys. Yet, the reclassification has faced opposition from reactionary lawmakers and anti-drug groups who continue to perpetuate myths and fear-mongering, arguing it could undermine public safety.

Industry leaders and advocates for social justice have welcomed the move, anticipating that it will reduce tax burdens and improve access to banking services for cannabis businesses, which have long been excluded from the financial system. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), stated that the order "validates the experiences of tens of millions of Americans, as well as those of tens of thousands of physicians, who have long recognized that cannabis possesses legitimate medical utility."

The executive order marks a significant, if overdue, shift in federal drug policy, reflecting growing recognition of marijuana's medical applications and the urgent need for updated regulations to support research, industry growth, and social equity.